公众号 / 文章心脑血管急症消化、代谢与肾脏急症

当代外周动脉疾病的认识

Understanding peripheral arterial disease in the current era.
PubMed 文献 · Lancet · 2026-09-22
一句话结论外周动脉疾病常长期无症状、确诊时已晚期,5年死亡率30%-50%,需重视其被低估、漏诊和治疗不足的问题。

该Lancet临床系列指出,动脉粥样硬化性心血管疾病领域传统上聚焦心脑血管事件,而下肢外周动脉疾病患病率上升、负担加重,这种侧重可能造成血管风险认知偏差。外周动脉疾病患者常无症状数年至数十年,确诊时已处晚期,5年总死亡率达30%-50%,甚至超过严重癌症和急性心肌梗死。与心脑血管疾病相比,外周动脉疾病在研究、临床实践及患者对预防、生活方式和药物治疗的依从性方面均受较低优先关注。系列共三篇:本文聚焦外周动脉粥样硬化的全球重要性及驱动因素;第2篇介绍从危险因素优化、最佳药物治疗到创新腔内和传统外科治疗的现代综合治疗;第3篇深入探讨全球负担、长期结局及地区、性别和社会经济差异。

要点

  • 外周动脉疾病患者常无症状数年至数十年,确诊时多已晚期,此时5年总死亡率达30%-50%。
  • 该5年死亡率甚至超过严重癌症和急性心肌梗死的结局,提示其预后被严重低估。
  • 与心脑血管疾病相比,外周动脉疾病在研究、临床实践和患者对预防、生活方式及药物治疗的依从性上均受较低优先关注。
  • 尽管各动脉粥样硬化亚组常见危险因素相似,但病理生理细节、病变模式及指南推荐依从性存在关键差异。
  • 系列第2篇提出按患者个体组合危险因素优化、最佳药物治疗、创新腔内手术和传统外科治疗的阶梯式整合照护。

适用人群与场景

  • 面向广泛跨学科社区,尤其是全科和内科每天接诊外周动脉疾病患者的医生。
  • 原文未明确列出纳入或排除标准。

诊断标准与关键阈值

  • 原文未提及具体的诊断标准、评分界值或启动/停止阈值。

处置流程与药物剂量

  • 第2篇提出按整合照护和阶梯式方法,将危险因素优化、最佳药物治疗、创新腔内手术和传统外科治疗按患者个体组合。
  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 外周动脉疾病患者常长期无症状,确诊时已处晚期,此时5年总死亡率达30%-50%,需警惕漏诊和延迟诊断。

研究设计与关键结果

  • 本文为Lancet临床系列三篇论文中的第一篇,聚焦外周动脉粥样硬化的全球重要性及其驱动因素。
  • 文中引用数据:外周动脉疾病确诊时5年总死亡率30%-50%。

证据类型、等级与局限

  • 证据类型为临床系列综述/专家意见,原文未给出证据等级或推荐强度。
  • 局限:原文未报告系统检索方法或原始研究数据,属叙述性系列文章。

对床旁实践的改变

  • 提示急诊/ICU医生不应仅关注心脑血管事件,对存在动脉粥样硬化危险因素者应警惕下肢外周动脉疾病可能长期无症状而漏诊。
  • 强调外周动脉疾病确诊时预后极差(5年死亡率30%-50%),需重视早期识别和长期管理。
  • 原文未提供急诊/ICU特定的筛查流程或药物方案,不能据此改变具体抢救或ICU处置。

指南或共识出处

  • Lancet临床系列(Clinical Series)三篇论文,本文为第1篇;原文未提供具体指南或共识名称及年份。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

Atherosclerotic cardiovascular disease is the primary driver of premature death in global populations in recent decades. Mortality statistics, most publications, and guidelines in the atherosclerotic cardiovascular disease field have traditionally focused on cardiac and cerebrovascular adverse events and causes of death. However, given the increasing prevalence of lower extremity peripheral arterial disease and its expanding burden on global health systems, such an emphasis might represent a skewed perception of vascular risk within the broader atherosclerotic spectrum. Although common risk factors appear similar in all atherosclerotic cardiovascular disease subgroups, several crucial differences exist, including pathophysiological details and lesion patterns, as well as adherence to guideline-based recommendations. Individuals with peripheral arterial disease frequently remain asymptomatic for many years, often decades, and are typically diagnosed only at an advanced stage of the condition. By this time, however, the expected long-term outcomes are already extremely poor. When diagnosed at this point, the overall 5-year mortality is between 30% and 50%, thus even surpassing outcomes of severe cancer and acute myocardial infarction. Compared with cardiac and cerebrovascular disease, peripheral arterial disease receives lower priority in research and clinical practice, which is compounded by poor patient adherence to preventive care, lifestyle modification, and pharmacological therapy. This clinical Series of three papers aims to improve this distressing situation. For this purpose, it is important to recognise the underacknowledgment, underdiagnosis, and undertreatment of peripheral arterial disease and to understand the complex inter-relationships behind it before suitable interdisciplinary measures can be initiated. In this Series paper, we want to reach the broad interdisciplinary community, and above all, those who see these patients every day in general practice and internal medicine. The focus is primarily on the global importance of peripheral atherosclerosis and its drivers. In paper 2 of this Series, readers are introduced to modern complementary therapy, ranging from the optimisation of risk factors and optimal pharmacological therapies to innovative endovascular procedures and traditional surgical treatments. In the sense of integrated care and a stepwise approach, the described therapy alternatives can be combined individually for each patient. Paper 3 of this Series provides readers with a deep insight into the global significance and burden of peripheral arterial disease. Since this disease is primarily characterised by its long-term, chronically progressive course, improving long-term outcomes represents a central aspect of this paper. It aims to further illuminate striking disparities between geographical regions, sexes, and socioeconomic groups. With strong recommendations, this clinical Series can help to guide both clinicians and policy makers towards effective preventive measures.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Behrendt CA, Norgren L, Nicolajsen CW, et al. Understanding peripheral arterial disease in the current era. Lancet. 2026. PMID: 42772316. doi:10.1016/S0140-6736(26)00846-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。